MEI Pharma Inc to Post Q2 2019 Earnings of ($0.12) Per Share, Oppenheimer Forecasts (MEIP)
MEI Pharma Inc (NASDAQ:MEIP) – Equities research analysts at Oppenheimer issued their Q2 2019 earnings per share estimates for shares of MEI Pharma in a report issued on Monday, December 3rd. Oppenheimer analyst L. Cann expects that the company will earn ($0.12) per share for the quarter.
MEI Pharma (NASDAQ:MEIP) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.02). The company had revenue of $0.49 million during the quarter, compared to analysts’ expectations of $0.38 million. MEI Pharma had a negative return on equity of 71.32% and a negative net margin of 2,508.05%.
Shares of MEI Pharma stock opened at $2.58 on Thursday. The company has a market capitalization of $199.15 million, a price-to-earnings ratio of -3.49 and a beta of 2.18. MEI Pharma has a one year low of $1.79 and a one year high of $5.14.
A number of institutional investors have recently made changes to their positions in MEIP. Wasatch Advisors Inc. purchased a new position in MEI Pharma in the 2nd quarter worth approximately $1,003,000. Bailard Inc. bought a new stake in shares of MEI Pharma in the 2nd quarter worth approximately $571,000. Keybank National Association OH bought a new stake in shares of MEI Pharma in the 2nd quarter worth approximately $102,000. NEA Management Company LLC bought a new stake in shares of MEI Pharma in the 2nd quarter worth approximately $22,539,000. Finally, Dimensional Fund Advisors LP grew its position in shares of MEI Pharma by 4.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 445,698 shares of the company’s stock worth $1,756,000 after buying an additional 17,562 shares during the last quarter. 50.79% of the stock is currently owned by institutional investors and hedge funds.
About MEI Pharma
MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Featured Story: Do Tariffs Work?
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.